DRugwatch BlogRSS 2.0

DRugwatch Blog > June 2010 > ASCO 2010: Emerging agents to change the landscape of ovarian cancer treatment

ASCO 2010: Emerging agents to change the landscape of ovarian cancer treatment

Kiran MeekingsWritten by: Kiran Meekings

SUMMARY
With few treatment options and a poor prognosis, ovarian cancer represents a considerable opportunity for drug developers. Currently available chemotherapeutic agents have little impact on improving the prognosis of patients whilst ovarian cancer is one of the few indications with no approved targeted therapies.  However, this may be set to change following the presentation of positive clinical trial results at ASCO.  We anticipate Roche’s Avastin will be approved for the first-line ovarian cancer setting in 2011, adding $1bn to the drug’s sales, whilst encouraging results of Amgen’s AMG386, Eisai’s farletuzumab, AstraZeneca’s olaparib and Sunesis’ voreloxin call for further development.  If the early-stage promise of these first-in-class compounds is substantiated in Phase III, we would anticipate the ovarian cancer market expanding significantly during our forecast period.

ANALYSIS
  • The much-awaited results of Avastin in ovarian cancer were presented yesterday in the plenary session at ASCO.  The results demonstrated that treatment of newly-diagnosed ovarian cancer with chemotherapy and Avastin, followed by maintenance Avastin, significantly improved progression-free survival (PFS): The risk of progression decreased by 28% compared to chemotherapy alone.
  • We anticipate these results will pave the way for approval of Avastin in both the US and EU for induction and maintenance use in the newly diagnosed ovarian cancer population.  We expect that approval in this setting will add nearly $1bn in sales in 2016.
  • Phase II results of Amgen’s first-in-class Ang1 and Ang 2-inhibiting peptibody, AMG386, were presented today, Monday, at ASCO.  Angiopoietin molecules are known to interact with Tie2 and are pivotal players in the angiogenic process.  Thus, inhibition of the angiopoietin-Tie2 interaction may be a new strategy in the fight against metastatic cancer.
  • The results showed that AMG 386 combined with weekly paclitaxel was highly efficacious and tolerable, with a manageable safety profile.  PFS, the primary endpoint, significantly increased from 4.6 months with placebo to 7.2 months in the high-dose AMG 386 arm, suggesting further development of the compound was warranted.  Phase III trials are in planning.
  • Final Phase II data of farletuzumab in platinum-sensitive relapsed ovarian cancer were also presented.  Farletuzumab is an antibody against folate receptor alpha, which is over-expressed in approximately 90% of ovarian cancers. The Phase II trial involved treating patients with both monotherapy and combination farletuzumab.  There was a marked response to the drug, with 89% of patients exhibiting normalization of their CA-125 levels and an overall response rate (ORR) of 70%.  The compound is currently being investigated in Phase III trials in the same setting.
  • PARP inhibitors have been touted for their potential in BRCA-mutated and serous ovarian cancer.  However, all studies to-date have only shown an effect when combined with chemotherapy.  However, results presented at ASCO on Saturday demonstrated that monotherapy olaparib is also an active therapy in high-grade serous ovarian cancer, regardless of BRCA mutation status.  This was shown not to be the case in breast cancer, where monotherapy olaparib did not exert an efficacious effect.  This positive result has the potential to expand the PARP inhibitor market and provide another treatment option for ovarian cancer patients.
  • Lastly, positive data was also reported for the first-in-class quinolone derivative voreloxin in platinum-resistant ovarian cancer.  The ORR of 11%, 12 week disease control rate of 48% and PFS of 84 days was in line with results produced by pegylated liposomal doxorubicin in the same setting.  Adverse events were manageable although a 9% rate of febrile neutropenia will require careful monitoring of patients.  However, the great unmet need in this population of patients and encouraging efficacy data encourages further development.

Posted on: 6/8/2010 1:24:45 PM | with 0 comments


Tags: Conference Commentary, Kiran Meekings, Oncology

Trackback URL: http://decisionresources.com/trackback/b1b5e3f5-ae20-4281-9e40-1cae93dd27e2/ASCO-2010--Emerging-agents-to-change-the-landscape-of-ovarian-cancer-treatment.aspx?culture=en-US

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
New Year, new resolutions, new drugs
Post date:
12/17/2014 10:53:24 AM
Post Summary:
 Contributors: Tim Blackstock

It’s a wonderful time of the year: spending quality time with friends and family, and eating good food. And then it’s January, and you hop on the scales – and then you hop off quickly in disbelief – how can it take such a short time to add so many pounds when it takes so long to lose just a few?!

Post title:
Pfizer Increases Enrollment by 40% in the SPIRE Cardiovascular Outcomes Trials for PCSK9 Inhibitor Bococizumab
Post date:
11/11/2014 9:36:25 AM
Post Summary:
Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).

Post title:
Obesity Week 2014 - Belviq gets the combination treatment
Post date:
11/7/2014 10:07:43 AM
Post Summary:
Gideon HeapContributor: Gideon Heap

Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.


Post title:
What’s going to be Hot at the 2014 AHA Scientific Sessions?
Post date:
10/22/2014 5:22:24 PM
Post Summary:
  Contributor: Conor Walsh

 This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

  • Risk and benefit of dual antiplatelet therapy (DAPT),
  • Anti-lipid therapy and prevention of coronary artery disease,
  • Treatment of structural heart disease
  • Drugs, devices and systems of care for ischemic heart disease.

Post title:
Advancing the Treatment of TKI-refractory NSCLC
Post date:
10/9/2014 1:33:46 PM
Post Summary:
Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

Decision Resources Group brands include: